Dr. Jonathan Trent discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Trabectedin was approved in the United States after a promising phase III study that consisted of 518 patients who had previously been treated with anthracycline. Trabectedin was approved for use in patients with soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, on October 23, 2015.
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More